Efficacy DataThe treatment achieved high rates of MRD negativity at 93.3%, indicating strong treatment efficacy.
Regulatory ProspectsThe probability of accelerated approval based on iMMagine-1 outcomes in 2026 is considered very high by analysts, given the excellent benefit/harm demonstrated in the study.
Safety ProfileAnito-cel's safety profile shows no delayed or non-immune effector cell-associated neurotoxicity syndrome (ICANS) neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome.